WO2023046085 - TPO MIMETIC FUSION PROTEINS AND METHODS OF USE
National phase entry:
Publication Number
WO/2023/046085
Publication Date
30.03.2023
International Application No.
PCT/CN2022/120948
International Filing Date
23.09.2022
Title **
[English]
TPO MIMETIC FUSION PROTEINS AND METHODS OF USE
[French]
PROTÉINES DE FUSION MIMÉTIQUES TPO ET PROCÉDÉS D'UTILISATION DE LA SOUMISSION DE LISTAGE DE SÉQUENCES EN TANT QUE FICHIER DE TEXTE ASCII
Applicants **
SICHUAN CLOVER BIOPHARMACEUTICALS, INC.
Inventors
LIANG, Peng
Priority Data
PCT/CN2021/120388
24.09.2021
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3576 | |
| EPO | Filing, Examination, Granting | 51231 | |
| Japan | Filing, Examination, Granting | 3889 | |
| South Korea | Filing, Examination, Granting | 5751 | |
| USA | Filing, Examination, Granting | 19340 |
Total:
83,787
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The recombinant peptides and proteins having thrombopoietin (TPO) activities, e.g., thrombopoietin mimetic peptides that are TPO receptor (TPOR) agonists. The recombinant peptides or proteins comprise a recombinant human p75 TNF receptor and TPO mimetic peptides linked by an Fc fragment of IgG1. The recombinant peptides form a homodimer by inter-chain disulfide bond in the Fc region and comprise six TPOR binding and/or activating domain in the C-terminus. The recombinant peptides or proteins provided herein are useful for increasing platelet count, e.g., for treating thrombocytopenia. The methods for producing the recombinant peptides and proteins, formulations, and therapeutic methods.[French]
L'invention concerne des peptides et des protéines de recombinaison ayant des activités de thrombopoïétine (TPO), par exemple, des peptides mimétiques de thrombopoïétine qui sont des agonistes du récepteur de la thrombopoïétine (TPOR). Les peptides ou les protéines de recombinaison comprennent un récepteur de TNF p75 humain recombinant et des peptides mimétiques de TPO liés par un fragment Fc de IgG1. Les peptides de recombinaison forment un homodimère par liaison disulfure inter-chaîne dans la région Fc et comprennent six domaines de liaison et/ou d'activation TPOR dans l'extrémité C-terminale. Les peptides ou les protéines de recombinaison selon l'invention sont utiles pour augmenter le nombre de plaquettes, par exemple pour traiter la thrombocytopénie. L'invention concerne également des procédés de production des peptides et protéines de recombinaison, des formulations et des méthodes thérapeutiques.